Skip to Content

Markets
Technicals
Companies
Earnings
Close-Up
Themes

News

Market and company headlines

COAGAll

Loading

A personal project for following the US markets. Free, ad-free and open source.

Weekly Recap

Every Sunday morning: the week's earnings behind you and the calendar ahead, in one email.

Get It by Email

Market

Markets
Companies
Stock Screener
Macro
Earnings
Technical Analysis
Calendar
Compare
Thematic Lists
Famous Investors

Reading

Guide
Close-Up
Community
News
Brief Archive
Glossary
Tax Calculator
RSS

Account

Watchlist
My Posts
Bell Report
Portfolio
Settings
Privacy

© 2026 Opening BellPrivacy About What's New ContactNot Investment AdviceAhmet Akyapı

Markets Earnings Close-Up Menu

Nasdaq 100 · QQQ675.64− 0.55%S&P 500 · SPY750.64− 0.27%Dow Jones · DIA522.49− 0.16%Russell 2000 · IWM280.87− 0.58%

Hemab Therapeutics Holdings (NASDAQ:COAG) Posts Wider Q3 Loss as Pipeline Catalysts Lift Stock
Hemab Therapeutics posts wider Q3 loss on zero revenue, but Phase 3 pipeline progress and cash runway into 2029 keep investors focused and shares rising.
ChartMill08:419 Hours AgoCOAG−9.4%

05:00-09:00Today2 Stories

Hemab Therapeutics Holdings, Inc. (COAG) Q3 2026 Earnings Call Transcript
Hemab Therapeutics Holdings, Inc. (COAG) Q3 2026 Earnings Call November 10, 2026 8:00 AM ESTCompany ParticipantsBenny Sorensen - President, CEO &...
SeekingAlpha08:31COAG−9.4%
Hemab Therapeutics Hldgs Q3 2026 Earnings Call Transcript
Hemab Therapeutics Hldgs (NASDAQ:COAG) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by
Benzinga05:03COAG−9.4%

03:00Today1 Story

Hemab Therapeutics Hldgs Q3 EPS $(0.58) Misses $(0.52) Estimate
Hemab Therapeutics Hldgs (NASDAQ:COAG) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.52) by 11.54 percent.
Benzinga03:06COAG−9.4%

04:00-08:00Yesterday2 Stories

Hemab Therapeutics Initiates SOLARA, a Pivotal Phase 3 Trial of Sutacimig in Glanzmann Thrombasthenia
Hemab’s first Phase 3 trial to evaluate once-weekly subcutaneous sutacimig in approximately 75 participants with Glanzmann thrombasthenia Single-arm design with a 24-week run-in followed by 48 weeks of treatment; primary endpoint is annualized treated bleed rate CAMBRIDGE, Mass. and COPENHAGEN, Denmark, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sus
Yahoo07:00COAG−9.4%
LifeSci Capital Initiates Coverage On Hemab Therapeutics Hldgs with Outperform Rating, Announces Price Target of $65
LifeSci Capital initiates coverage on Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Outperform rating and announces Price Target of $65.
Benzinga04:17

03:00Yesterday1 Story

Hemab Therapeutics Initiates SOLARA, Pivotal Phase 3 Trial Evaluating Sutacimig As Potential Prophylactic Treatment For People With Glanzmann Thrombasthenia
Hemab’s first Phase 3 trial to evaluate once-weekly subcutaneous sutacimig in approximately 75 participants with Glanzmann thrombastheniaSingle-arm design with a 24-week run-in followed by 48 weeks of treatment; primary
Benzinga03:08COAG−9.4%

05:00-10:00Nov 42 Stories

Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the 68th ASH Annual Meeting and Exposition
First clinical data for sutacimig in Factor VII deficiency (FVIID) shows multi-fold accumulation of endogenous FVII(a) with shortening of prothrombin time after a single subcutaneous dose in initial participants of the Phase 2b study Preclinical data show HMB-003 reduced severe menstrual bleeding in a cynomolgus monkey model of menstrual bleeding CAMBRIDGE, Mass. and COPENHAGEN, Denmark, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (Nasdaq:COAG), a clinical-stage biotechnology company de
Yahoo09:05COAG−9.4%
Hemab Therapeutics To Present Two Presentations At American Society Of Hematology Annual Meeting
Hemab Therapeutics (Nasdaq:COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced two
Benzinga05:13

07:00Nov 31 Story

Hemab Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 10, 2026
CAMBRIDGE, Mass. and COPENHAGEN, Denmark, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced that it will host a conference call on Tuesday, November 10, at 8:00 a.m. ET to discuss its financial results and provide a corporate update for the third quarter ended September 30, 2026. Listeners can register for
Yahoo07:00COAG−9.4%

COAG

▼−9.4%

COAG▼−9.4%